|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 919.75 INR | -1.01% |
|
-0.51% | -5.34% |
| Dec. 10 | Indian Equities Extend Losses as Investors Turn Cautious Ahead of US Rate Decision | MT |
| Dec. 10 | Zydus Lifesciences Launches Denosumab Biosimilar | MT |
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 6.9 | 6.36 | 6.66 | 10.31 | 11.21 | |||||
Return on Total Capital | 8.35 | 7.68 | 8.08 | 12.95 | 14.19 | |||||
Return On Equity % | 16.4 | 13.96 | 10.82 | 18.9 | 19.28 | |||||
Return on Common Equity | 18.26 | 14.95 | 11.39 | 20.55 | 20.67 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 64.53 | 62.75 | 62.46 | 67.29 | 71.87 | |||||
SG&A Margin | 22.03 | 21.27 | 21.84 | 21.72 | 22.18 | |||||
EBITDA Margin % | 21.88 | 21.78 | 20.5 | 26.89 | 29.39 | |||||
EBITA Margin % | 18.22 | 18 | 17.02 | 23.73 | 26.49 | |||||
EBIT Margin % | 17.38 | 17.22 | 16.55 | 23.22 | 25.64 | |||||
Income From Continuing Operations Margin % | 14.47 | 15.54 | 12.16 | 20.21 | 20.1 | |||||
Net Income Margin % | 14.13 | 29.4 | 11.37 | 19.74 | 19.47 | |||||
Net Avail. For Common Margin % | 14.13 | 14.68 | 11.4 | 19.63 | 19.47 | |||||
Normalized Net Income Margin | 10.25 | 10.14 | 10.87 | 14.84 | 16.25 | |||||
Levered Free Cash Flow Margin | 10.84 | 4.49 | 6.16 | 8.24 | 12.21 | |||||
Unlevered Free Cash Flow Margin | 11.5 | 4.95 | 6.61 | 8.38 | 12.46 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.63 | 0.59 | 0.64 | 0.71 | 0.7 | |||||
Fixed Assets Turnover | 2.41 | 2.39 | 2.6 | 2.85 | 3.26 | |||||
Receivables Turnover (Average Receivables) | 4.45 | 4.72 | 4.44 | 4.06 | 5.03 | |||||
Inventory Turnover (Average Inventory) | 1.78 | 1.63 | 1.81 | 1.87 | 1.77 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.11 | 1.56 | 1.81 | 2.14 | 1.89 | |||||
Quick Ratio | 0.57 | 0.95 | 1.05 | 1.3 | 1.12 | |||||
Operating Cash Flow to Current Liabilities | 0.42 | 0.27 | 0.49 | 0.6 | 0.75 | |||||
Days Sales Outstanding (Average Receivables) | 82.06 | 77.32 | 82.13 | 90.22 | 72.59 | |||||
Days Outstanding Inventory (Average Inventory) | 205.29 | 223.26 | 201.17 | 196.21 | 206.16 | |||||
Average Days Payable Outstanding | 133.66 | 128.5 | 126.2 | 121.15 | 114.9 | |||||
Cash Conversion Cycle (Average Days) | 153.7 | 172.08 | 157.1 | 165.28 | 163.85 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 30.91 | 22.15 | 6.07 | 3.72 | 12.21 | |||||
Total Debt / Total Capital | 23.61 | 18.14 | 5.72 | 3.59 | 10.88 | |||||
LT Debt/Equity | 4.18 | 1.98 | 0.1 | 0.11 | 0.12 | |||||
Long-Term Debt / Total Capital | 3.2 | 1.62 | 0.09 | 0.11 | 0.11 | |||||
Total Liabilities / Total Assets | 37.49 | 31.45 | 23.56 | 24.52 | 29.15 | |||||
EBIT / Interest Expense | 16.36 | 22.98 | 22.73 | 103.16 | 63.75 | |||||
EBITDA / Interest Expense | 20.68 | 29.18 | 28.28 | 119.86 | 73.23 | |||||
(EBITDA - Capex) / Interest Expense | 15.36 | 18.67 | 20.07 | 99.25 | 54.91 | |||||
Total Debt / EBITDA | 1.39 | 1.26 | 0.34 | 0.16 | 0.47 | |||||
Net Debt / EBITDA | 1.06 | 0.07 | 0 | -0.1 | -0.35 | |||||
Total Debt / (EBITDA - Capex) | 1.87 | 1.98 | 0.47 | 0.19 | 0.63 | |||||
Net Debt / (EBITDA - Capex) | 1.43 | 0.12 | 0 | -0.12 | -0.47 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 5.96 | 5.98 | 14.08 | 13.4 | 18.9 | |||||
Gross Profit, 1 Yr. Growth % | 6.25 | 1.26 | 14.25 | 22.17 | 26.98 | |||||
EBITDA, 1 Yr. Growth % | 19.69 | -2.65 | 11.51 | 48.74 | 29.92 | |||||
EBITA, 1 Yr. Growth % | 23.26 | -4.03 | 13.19 | 58.12 | 32.73 | |||||
EBIT, 1 Yr. Growth % | 24.85 | -3.88 | 15.31 | 59.11 | 31.3 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 81.42 | 5.31 | -11.64 | 88.4 | 18.3 | |||||
Net Income, 1 Yr. Growth % | 81.34 | 110.32 | -56.31 | 96.88 | 17.26 | |||||
Normalized Net Income, 1 Yr. Growth % | 38.73 | -4.45 | 21.05 | 54.79 | 30.21 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 81.34 | 1.82 | -11.65 | 95.97 | 18.63 | |||||
Accounts Receivable, 1 Yr. Growth % | -14.63 | 6.81 | 32.23 | 18.19 | -22.9 | |||||
Inventory, 1 Yr. Growth % | 16.03 | 14.93 | -8.23 | 0.84 | 14.59 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 2.25 | 1.41 | 6.29 | 1.29 | 6.44 | |||||
Total Assets, 1 Yr. Growth % | 0.84 | 16.37 | -7.34 | 13.68 | 27.05 | |||||
Tangible Book Value, 1 Yr. Growth % | 78.17 | 63.94 | 10.59 | 2.85 | 29.57 | |||||
Common Equity, 1 Yr. Growth % | 25.22 | 30.84 | 3.04 | 13.21 | 20.8 | |||||
Cash From Operations, 1 Yr. Growth % | 12.33 | -36.12 | 27.76 | 20.05 | 112.02 | |||||
Capital Expenditures, 1 Yr. Growth % | -5.54 | 40.82 | -14.28 | -12.06 | 88.9 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 39.08 | -59.93 | 40.72 | 51.76 | 76.77 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 25.95 | -58.14 | 38.04 | 43.73 | 77.37 | |||||
Dividend Per Share, 1 Yr. Growth % | 0 | -28.57 | 140 | -50 | 266.67 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 7.1 | 3.49 | 9.4 | 13.74 | 16.12 | |||||
Gross Profit, 2 Yr. CAGR % | 8.31 | 2.19 | 6.68 | 18.14 | 24.55 | |||||
EBITDA, 2 Yr. CAGR % | 5.39 | 9.75 | 1.73 | 28.79 | 39.02 | |||||
EBITA, 2 Yr. CAGR % | 4.42 | 10.94 | 1.23 | 33.78 | 44.87 | |||||
EBIT, 2 Yr. CAGR % | 4.73 | 11.85 | 2.12 | 35.45 | 44.54 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 7.27 | 40.35 | -3.54 | 29.03 | 49.29 | |||||
Net Income, 2 Yr. CAGR % | 7.43 | 95.29 | -4.15 | -7.26 | 51.94 | |||||
Normalized Net Income, 2 Yr. CAGR % | 5.45 | 17.76 | 7.54 | 36.88 | 41.97 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 7.43 | 38.03 | -5.15 | 31.59 | 52.47 | |||||
Accounts Receivable, 2 Yr. CAGR % | -11.03 | -4.51 | 18.84 | 25.01 | -4.54 | |||||
Inventory, 2 Yr. CAGR % | 9.72 | 15.48 | 2.7 | -3.8 | 7.49 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 3.23 | 1.83 | 3.82 | 3.76 | 3.83 | |||||
Total Assets, 2 Yr. CAGR % | 0.85 | 8.33 | 3.84 | 2.64 | 20.18 | |||||
Tangible Book Value, 2 Yr. CAGR % | 38.77 | 70.91 | 34.65 | 6.65 | 15.44 | |||||
Common Equity, 2 Yr. CAGR % | 11.84 | 28 | 16.11 | 8 | 16.94 | |||||
Cash From Operations, 2 Yr. CAGR % | 60.28 | -15.28 | -9.65 | 23.85 | 58.76 | |||||
Capital Expenditures, 2 Yr. CAGR % | -10.13 | 15.33 | 9.87 | -13.17 | 28.89 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 308.87 | -23.71 | -21.21 | 46.14 | 63.56 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 182.95 | -25.94 | -20.58 | 40.85 | 59.44 | |||||
Dividend Per Share, 2 Yr. CAGR % | 0 | -15.48 | 30.93 | 9.54 | 35.4 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 8.25 | 5.06 | 6.54 | 10.72 | 15.43 | |||||
Gross Profit, 3 Yr. CAGR % | 8.36 | 4.86 | 5.49 | 11.61 | 21.02 | |||||
EBITDA, 3 Yr. CAGR % | 5.14 | 3.78 | 8.59 | 15.46 | 29.17 | |||||
EBITA, 3 Yr. CAGR % | 3.79 | 2.87 | 9.54 | 17.46 | 33.43 | |||||
EBIT, 3 Yr. CAGR % | 4.13 | 3.2 | 10.72 | 18.39 | 34.05 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 6.1 | 7.71 | 20.29 | 20.58 | 25.35 | |||||
Net Income, 3 Yr. CAGR % | 6.31 | 34.39 | 18.55 | 21.84 | 0.28 | |||||
Normalized Net Income, 3 Yr. CAGR % | 2.58 | 3.59 | 18.85 | 21.42 | 34.62 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 5.94 | 6.63 | 18.96 | 20.8 | 27.12 | |||||
Accounts Receivable, 3 Yr. CAGR % | -0.83 | -5.44 | 6.43 | 18.62 | 6.41 | |||||
Inventory, 3 Yr. CAGR % | 10.7 | 11.43 | 6.97 | 2.08 | 1.97 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 5.81 | 2.62 | 3.3 | 2.97 | 4.65 | |||||
Total Assets, 3 Yr. CAGR % | 9.76 | 5.78 | 2.83 | 7.03 | 10.2 | |||||
Tangible Book Value, 3 Yr. CAGR % | 1.77 | 46.7 | 47.83 | 23.09 | 13.8 | |||||
Common Equity, 3 Yr. CAGR % | 14.11 | 17.85 | 19.07 | 15.14 | 12.11 | |||||
Cash From Operations, 3 Yr. CAGR % | 53.01 | 17.96 | -2.84 | -0.67 | 47.67 | |||||
Capital Expenditures, 3 Yr. CAGR % | -6.63 | 4.38 | 4.47 | 2.01 | 12.51 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 33.49 | 91.25 | -3.39 | -1.97 | 55.56 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 40.77 | 51.63 | -6.16 | -3.22 | 51.96 | |||||
Dividend Per Share, 3 Yr. CAGR % | 0 | -10.61 | 19.68 | -5.01 | 63.86 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 9.88 | 10.24 | 7.68 | 8.23 | 10.27 | |||||
Gross Profit, 5 Yr. CAGR % | 9.28 | 10.3 | 7.05 | 9.62 | 12.74 | |||||
EBITDA, 5 Yr. CAGR % | 7.28 | 11.85 | 4.46 | 12.07 | 19.87 | |||||
EBITA, 5 Yr. CAGR % | 6.04 | 11.59 | 3.58 | 12.95 | 22.5 | |||||
EBIT, 5 Yr. CAGR % | 5.18 | 11.41 | 4.18 | 13.66 | 23.18 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 2.15 | 9.32 | 2.77 | 15.78 | 31.15 | |||||
Net Income, 5 Yr. CAGR % | 1.98 | 24.71 | 2 | 15.86 | 30.92 | |||||
Normalized Net Income, 5 Yr. CAGR % | 3.79 | 9.96 | 5.48 | 15.8 | 27.61 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 1.98 | 8.51 | 1.99 | 15.99 | 31.37 | |||||
Accounts Receivable, 5 Yr. CAGR % | 12.36 | 7.96 | 6.62 | 5.73 | 1.9 | |||||
Inventory, 5 Yr. CAGR % | 19.34 | 15.57 | 7.43 | 5.07 | 7.18 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 12.23 | 5.85 | 5.01 | 3.08 | 3.51 | |||||
Total Assets, 5 Yr. CAGR % | 17.75 | 12.8 | 7.35 | 4.51 | 9.45 | |||||
Tangible Book Value, 5 Yr. CAGR % | 7.06 | 18.51 | 13.83 | 29.13 | 33.91 | |||||
Common Equity, 5 Yr. CAGR % | 17.92 | 19.55 | 14.9 | 13.81 | 18.21 | |||||
Cash From Operations, 5 Yr. CAGR % | 11.7 | 9.91 | 23.94 | 20.29 | 18.25 | |||||
Capital Expenditures, 5 Yr. CAGR % | -2.36 | -16.37 | -0.35 | -3.03 | 13.63 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 19 | -19.09 | 9.05 | 75.07 | 19.25 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 19.54 | -17.17 | 12.85 | 49.82 | 16 | |||||
Dividend Per Share, 5 Yr. CAGR % | 1.81 | -4.82 | 11.38 | -3.04 | 25.74 |
- Stock Market
- Equities
- ZYDUSLIFE Stock
- Financials Zydus Lifesciences Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
















